Skip to main content
. Author manuscript; available in PMC: 2014 Jul 19.
Published in final edited form as: ACS Chem Biol. 2013 May 13;8(7):1567–1575. doi: 10.1021/cb400170b

Figure 5. EX VIVO pharmacodynamic analysis of PARP inhibitors.

Figure 5

(A) Method design. (B–C) PARP inhibition curves for ABT-888 (B) and olaparib (C) in PBMCs treated with 100 μM H2O2 for 5 min. Each experiment was performed with PBMCs isolated from a single donor, respectively, on different days (inter-day variability). Data represent means ± SEM from three independent experiments. Curves were fitted using a sigmoidal model with variable slope.